← Back to Search

Treatment for Becker Muscular Dystrophy (GRASP-01-002 Trial)

N/A
Recruiting
Led By Nicholas E. Johnson, MD
Research Sponsored by Virginia Commonwealth University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2 years
Awards & highlights

Summary

This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD)

Eligible Conditions
  • Becker Muscular Dystrophy
  • Muscular Dystrophy
  • Duchenne Muscular Dystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
100-Meter Timed Test
4-Stair Climb
HAND HELD DYNAMOMETRY (HHD) AND GRIP
+8 more
Other outcome measures
Biomarker Assessment - Blood Sampling
MAGNETIC RESONANCE IMAGING TRANSVERSE RELAXATION TIME (T2)
MAGNETIC RESONANCE SPECTROSCOPY TRANSVERSE RELAXATION TIME (T2)
+1 more

Find a Location

Who is running the clinical trial?

Virginia Commonwealth UniversityLead Sponsor
710 Previous Clinical Trials
22,886,857 Total Patients Enrolled
Edgewise Therapeutics, Inc.Industry Sponsor
11 Previous Clinical Trials
787 Total Patients Enrolled
Nicholas E. Johnson, MDPrincipal InvestigatorVirginia Commonwealth University
2 Previous Clinical Trials
550 Total Patients Enrolled
~16 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top